J
Jacoline E C Bromberg
Researcher at Erasmus University Rotterdam
Publications - 103
Citations - 10921
Jacoline E C Bromberg is an academic researcher from Erasmus University Rotterdam. The author has contributed to research in topics: Primary central nervous system lymphoma & Rituximab. The author has an hindex of 31, co-authored 95 publications receiving 9357 citations. Previous affiliations of Jacoline E C Bromberg include Erasmus University Medical Center & Utrecht University.
Papers
More filters
Journal ArticleDOI
OS7.1 Impact of the addition of Rituximab to standard therapy with high dose methotrexate on health-related quality of life in primary central nervous system lymphoma patients
M. van der Meulen,L Dirven,Katerina Bakunina,M J B Taphoorn,M. J. van den Bent,Samar Issa,J.K. Doorduijn,Jacoline E C Bromberg +7 more
TL;DR: Treatment with Rituximab resulted in improved HRQoL, but the addition of RitUXimab to standard chemotherapy did not further impact HRQeL over time, and WBRT did not result in deterioration of HRZoL up to 2 years of follow-up.
Journal ArticleDOI
Comprehensive microRNA expression profiling in cerebrospinal fluid distinguishes between neurological disease classes.
Sarah Grasedieck,Medhanie A. Mulaw,Nadine Sperb,Katja Wessinger,Arefeh Rouhi,Martin Bommer,Jacoline E C Bromberg,Markus Otto,Hayrettin Tumani,Christine A. F. von Arnim,Daniel Mertens,Florian Kuchenbauer +11 more
TL;DR: It is asked whether it is possible to build an atlas comprising four major CNS pathology classes: inflammatory, malignant, autoimmune, and neurodegenerative diseases, in comparison to neurological controls, exclusively based on miRNAs isolated from patient cerebrospinal fluid.
Journal ArticleDOI
Ncog-05. impact of additional rituximab to standard therapy on cognitive performances in primary central nervous system lymphoma patients
Matthijs van der Meulen,Linda Dirven,Esther J. J. Habets,Katerina Bakunina,Martin J B Taphoorn,Martin J. van den Bent,Samar Issa,Jeanette K. Doorduijn,Jacoline E C Bromberg +8 more
TL;DR: Cognitive performance remained stable or improved after treatment of primary central nervous system lymphoma patients with or without Rituximab and low-dose whole brain radiotherapy (WBRT), and addition of RitUXimab to standard treatment did not impact cognitive performance over time.
Journal ArticleDOI
At-56treatment of large low-grade oligodendroglial tumors with upfront procarbazine, lomustine, and vincristine chemotherapy with long follow-up: a retrospective cohort study with growth kinetics
Walter Taal,Karin van der Rijt,Winand N.M. Dinjens,Peter A. E. Sillevis Smitt,Agnes A. A. C. M. Wertenbroek,Jacoline E C Bromberg,Irene van Heuvel,Johan M. Kros,Martin J. van den Bent +8 more
TL;DR: This long-term follow-up study indicates that upfront PCV chemotherapy is associated with long PFS and OS and delays radiotherapy for a considerable period of time in patients with low-grade oligodendroglial tumors, in particular with combined 1p/19q loss.
Journal ArticleDOI
Sequential Matrix-RICE Therapy Followed By Autologous Stem Cell Transplant in Patients with Diffuse Large B-Cell Lymphoma and Secondary Central Nervous System Involvement: The International Extranodal Lymphoma Study Group-42 Phase II (MARIETTA) Trial
Andrés J.M. Ferreri,Jeanette K. Doorduijn,Chiara Cattaneo,Maria Giuseppina Cabras,Jeffery Smith,Fiorella Ilariucci,Franco Narni,Teresa Calimeri,Alessandro Re,Jahanzaib Khwaja,Barbara Botto,Claudia Cellini,Luca Nassi,Kim Linton,Pam McKay,Jacopo Olivieri,Caterina Patti,Francesca Re,Alessandro Fanni,Vikram Singh,Jacoline E C Bromberg,Kelly Cozens,Elisabetta Gastaldi,Nicola Cascavilla,Andrew Davies,Christopher P. Fox,Maurizio Frezzato,Wendy Osborne,Anna Marina Liberati,Urban Novak,Renato Zambello,Emanuele Zucca,Kate Cwynarski +32 more
TL;DR: A multicenter phase II trial addressing an intensified chemoimmunotherapy consolidated by ASCT in HIV-neg pts with SCNSL and finding if ≥41 pts were progression-free at 1 yr would be considered effective.